These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 38708616)
21. Cancer of the Nasal Cavity, Middle Ear and Accessory Sinuses - 15 Year Comparative Survival and Mortality Analysis by Age, Sex, Race, Stage, Grade, Cohort Entry Time-Period, Disease Duration and Topographic Primary Sites: A Systematic Review of 13,404 Cases for Diagnosis Years 2000-2017: (NCI SEER*Stat 8.3.8). Milano AF J Insur Med; 2024 Jul; 51(2):77-91. PubMed ID: 39266003 [TBL] [Abstract][Full Text] [Related]
22. Prognosis of patients with neuroendocrine tumor: a SEER database analysis. Man D; Wu J; Shen Z; Zhu X Cancer Manag Res; 2018; 10():5629-5638. PubMed ID: 30519109 [TBL] [Abstract][Full Text] [Related]
23. Non-Hodgkin Lymphoma - Nodal and Extranodal: 20-Year Comparative Mortality, Survival & Biologic Behavior Analysis by Age, Sex, Race, Stage, Cell Morphology/Histology, Cohort Entry Time-Period and Disease Duration: A Systematic Review of 384,651 Total NHL Cases Including 261,144 Nodal and 123,507 Extranodal Cases for Diagnosis Years 1975-2016: (SEER*Stat 8.3.6). Milano AF J Insur Med; 2023 Jul; 50(1):1-35. PubMed ID: 37725503 [TBL] [Abstract][Full Text] [Related]
24. Incidence trend and conditional survival estimates of gastroenteropancreatic neuroendocrine tumors: A large population-based study. Zhong Q; Chen QY; Xie JW; Wang JB; Lin JX; Lu J; Cao LL; Lin M; Tu RH; Huang ZN; Lin JL; Li P; Zheng CH; Huang CM Cancer Med; 2018 Jul; 7(7):3521-3533. PubMed ID: 29873204 [TBL] [Abstract][Full Text] [Related]
25. Incidence, survival, and prognostic nomogram of patients with small intestinal neuroendocrine tumors: A SEER population-based study. Peng Y; Xu B; Zhang F; Wu R; Tong S; Mao Z Medicine (Baltimore); 2024 Sep; 103(37):e39616. PubMed ID: 39287239 [TBL] [Abstract][Full Text] [Related]
26. A Population-Based Systematic Clinical Analysis With a Single-Center Case Series of Patients With Pulmonary Large Cell Neuroendocrine Carcinoma. Sun X; Wu Y; Shen J; Han C; Kang K; Liu Z; Zhang F Front Endocrinol (Lausanne); 2021; 12():759915. PubMed ID: 34925232 [TBL] [Abstract][Full Text] [Related]
27. Epidemiologic trends of and factors associated with overall survival in patients with neuroendocrine tumors over the last two decades in the USA. Wu P; He D; Chang H; Zhang X Endocr Connect; 2023 Dec; 12(12):. PubMed ID: 37924638 [TBL] [Abstract][Full Text] [Related]
28. Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States. Shah S; Gosain R; Groman A; Gosain R; Dasari A; Halfdanarson TR; Mukherjee S Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33916960 [TBL] [Abstract][Full Text] [Related]
30. Primary neuroendocrine tumors of the ovary: Management and outcomes. Pang L; Guo Z Cancer Med; 2021 Dec; 10(23):8558-8569. PubMed ID: 34773393 [TBL] [Abstract][Full Text] [Related]
31. Survival and prognostic factors for postoperative primary appendiceal cancer: a retrospective cohort study based on the Surveillance, Epidemiology, and End Results database. Wang Y; Geng Y; Hu W J Gastrointest Oncol; 2022 Jun; 13(3):1433-1443. PubMed ID: 35837159 [TBL] [Abstract][Full Text] [Related]
32. 20-Year Comparative Survival and Mortality of Cancer of the Stomach by Age, Sex, Race, Stage, Grade, Cohort Entry Time-Period, Disease Duration & Selected ICD-O-3 Oncologic Phenotypes: Milano AF J Insur Med; 2019; 48(1):5-23. PubMed ID: 31609640 [No Abstract] [Full Text] [Related]
33. The National Landscapes of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: Stable Trends in Black Populations and Late-Stage Tumors. Abboud Y; Pirquet C; Timmons K; Abboud I; Awadallah M; Al-Khazraji A; Hajifathalian K Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893144 [TBL] [Abstract][Full Text] [Related]
34. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Modlin IM; Champaneria MC; Chan AK; Kidd M Am J Gastroenterol; 2007 Jul; 102(7):1464-73. PubMed ID: 17391319 [TBL] [Abstract][Full Text] [Related]
35. Metastasis Prevalence and Survival of Patients with T1-2 Gastric Neuroendocrine Tumor Treated with Endoscopic Therapy and Surgery. Wang M; Cheng S; Zhu L; Xu T; Zhang J; Zhang Y; Ping J; Wang R Dig Dis Sci; 2022 Jul; 67(7):3228-3238. PubMed ID: 34272627 [TBL] [Abstract][Full Text] [Related]
36. Increasing incidence of duodenal neuroendocrine tumors: Incidental discovery of indolent disease? Fitzgerald TL; Dennis SO; Kachare SD; Vohra NA; Zervos EE Surgery; 2015 Aug; 158(2):466-71. PubMed ID: 26013986 [TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes for neuroendocrine tumors of the duodenum and ampulla of Vater: a population-based study. Randle RW; Ahmed S; Newman NA; Clark CJ J Gastrointest Surg; 2014 Feb; 18(2):354-62. PubMed ID: 24114680 [TBL] [Abstract][Full Text] [Related]
38. Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis. Tsikitis VL; Wertheim BC; Guerrero MA J Cancer; 2012; 3():292-302. PubMed ID: 22773933 [TBL] [Abstract][Full Text] [Related]
39. Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006. Navalkele P; O'Dorisio MS; O'Dorisio TM; Zamba GK; Lynch CF Pediatr Blood Cancer; 2011 Jan; 56(1):50-7. PubMed ID: 21108439 [TBL] [Abstract][Full Text] [Related]
40. Epidemiological trends of neuroendocrine tumours over three decades in Queensland, Australia. Wyld D; Wan MH; Moore J; Dunn N; Youl P Cancer Epidemiol; 2019 Dec; 63():101598. PubMed ID: 31539715 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]